Claims for Patent: 7,812,146

Summary for Patent: 7,812,146

Title:	Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor
Abstract:	The present invention relates to a hybrid Hepatocyte Growth Factor (HGF) gene which is prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA, which has a base sequence of SEQ ID NO: 2. The gene has high expression efficiency and simultaneously expresses two heterotypes of HGF and dHGF (deleted variant HGF). Further the gene may be used for treating or preventing ischemic or liver diseases.
Inventor(s):	Kim; Jong-Mook (Seoul, KR), Hahn; Woong (Goyang, KR), Park; Eun-Jin (Seoul, KR)
Assignee:	ViroMed Co., Ltd. (Seoul, KR)
Application Number:	10/944,277
Patent Claims:	1. A hybrid Hepatocyte Growth Factor (HGF) construct comprising: (a) a first cDNA which has the same sequence as exons 1-4 of the human HGF gene wherein said exons 1-4 are arranged in sequential order without an intron therebetween, or degenerates thereof which do not alter the amino acid sequence encoded by said first cDNA, (b) a polynucleotide that has the same sequence as intron 4 of a HGF gene or a functional fragment thereof, and (c) a second cDNA which has the same sequence as exons 5-18 of the human HGF gene wherein said exons 5-18 are arranged in sequential order without an intron therebetween, or degenerates thereof which do not alter the amino acid sequence encoded by said second cDNA; wherein (b) is located between (a) and (c); and the HGF construct simultaneously encodes two heterotypes of human HGF. 2. The hybrid HGF construct of claim 1, wherein the polynucleotide of (b) has the same sequence as the full intron 4 of the human HGF gene. 3. The hybrid HGF construct of claim 2, wherein said hybrid HGF construct comprises SEQ ID NO:2. 4. The hybrid HGF construct of claim 1, wherein polynucleotide of (b) has the same sequence as a fragment of intron 4 of the human HGF gene. 5. The hybrid HGF construct of claim 4, wherein said hybrid HGF construct comprises SEQ ID NO:19. 6. The hybrid HGF construct of claim 4, wherein said hybrid HGF construct comprises SEQ ID NO:20. 7. The hybrid HGF construct of claim 4, wherein said hybrid HGF construct comprises SEQ ID NO:21. 8. A vector comprising the hybrid HGF construct of claim 1. 9. The vector of claim 8, wherein said vector further comprises one or more sequences for regulating expression, a self-replication sequence, or a secretory signal. 10. The vector of claim 9, wherein said vector is selected from the group consisting of: pCK-HGF-X2, pCK-HGF-X3, pCK-HGF-X6, pCK-HGF-X7, pCK-HGF-X8, pCP-HGF-X2, pCPHGF-X3, pCP-HGF-X6, pCP-HGF-X7 and pCP-HGF-X8. 11. An isolated cell containing the vector of claim 8, wherein said cell is a mammalian cell, a bacterial cell or a yeast cell. 12. The cell of claim 11, wherein said cell is a mammalian cell. 13. The cell of claim 11, wherein said cell is a yeast cell. 14. The cell of claim 11, wherein said cell is an E. coli cell. 15. The cell of claim 14, wherein said cell is an E. coli Top10F' pCK-HGF-X7 (Deposit No. KCCM-10361) or E. coli Top10F' pCP-HGF-X7 (Deposit No. KCCM-10362) cell. 16. A pharmaceutical composition comprising the hybrid HGF construct of claim 1 and a carrier. 17. A method of producing a hybrid HGF protein comprising culturing the cell of claim 11 in a suitable medium and collecting the hybrid HGF protein. 18. A hybrid HGF construct comprising a polynucleotide having a nucleotide sequence not less than 90% identical to SEQ ID NO:2, wherein the polynucleotide having said nucleotide sequence simultaneously encodes two heterotypes of human HGF. 19. The hybrid HGF construct of claim 18, wherein said nucleotide sequence is not less than 95% identical to SEQ ID NO:2. 20. A hybrid HGF construct comprising a polynucleotide having a nucleotide sequence not less than 90% identical to SEQ ID NO:19, wherein the polynucleotide having said nucleotide sequence simultaneously encodes two heterotypes of human HGF. 21. The hybrid HGF construct of claim 20, wherein said nucleotide sequence is not less than 95% identical to SEQ lID NO:19. 22. A hybrid HGF construct comprising a polynucleotide having a nucleotide sequence not less than 90% identical to SEQ ID NO:20, wherein the polynucleotide having said nucleotide sequence simultaneously encodes two heterotypes of human HGF. 23. The hybrid HGF construct of claim 22, wherein said nucleotide sequence is not less than 95% identical to SEQ ID NO:20. 24. A hybrid HGF construct comprising a polynucleotide having a nucleotide sequence not less than 90% identical to SEQ ID NO:21, wherein the polynucleotide having said nucleotide sequence simultaneously encodes two heterotypes of human HGF. 25. The hybrid HGF construct of claim 24, wherein said nucleotide sequence is not less than 95% identical to SEQ ID NO:21. 26. A vector comprising the hybrid HGF construct of claim 18. 27. An isolated cell comprising the hybrid HGF construct of claim 18, wherein said cell is a mammalian cell, a bacterial cell or a yeast cell. 28. A pharmaceutical composition comprising the hybrid HGF construct of claim 18 and a carrier. 29. A method of producing a hybrid HGF protein comprising culturing the cell of claim 27 in a suitable medium and collecting the hybrid HGF protein. 30. A vector comprising the hybrid HGF construct of claim 20. 31. An isolated cell comprising the hybrid HGF construct of claim 20, wherein said cell is a mammalian cell, a bacterial cell or a yeast cell. 32. A pharmaceutical composition comprising the hybrid HGF construct of claim 20 and a carrier. 33. A method of producing a hybrid HGF protein comprising culturing the cell of claim 31 in a suitable medium and collecting the hybrid HGF protein. 34. A vector comprising the hybrid HGF construct of claim 22. 35. An isolated cell comprising the hybrid HGF construct of claim 22, wherein said cell is a mammalian cell, a bacterial cell or a yeast cell. 36. A pharmaceutical composition comprising the hybrid HGF construct of claim 22 and a carrier. 37. A method of producing a hybrid HGF protein comprising culturing the cell of claim 35 in a suitable medium and collecting the hybrid HGF protein. 38. A vector comprising the hybrid HGF construct of claim 24. 39. An isolated cell comprising the hybrid HGF construct of claim 24, wherein said cell is a mammalian cell, bacterial cell or yeast cell. 40. A pharmaceutical composition comprising the hybrid HGF construct of claim 24 and a carrier. 41. A method of producing a hybrid HGF protein comprising culturing the cell of claim 39 in a suitable medium and collecting the hybrid HGF protein. 42. A hybrid HGF construct comprising: (a) a first cDNA which has the same sequence as human HGF exons 1-4wherein said exons 1-4 are arranged in sequential order without an intron therebetween, or degenerates thereof which do not alter the amino acid sequence encoded by said first cDNA, (b) a polynucleotide comprising 483-727 of SEQ ID NO: 2 and 5117-5423 of SEQ ID NO: 2, and (c) a second cDNA which has the same sequence as human HGF exons 5-18 wherein said exons 5-18 are arranged in sequential order without an intron therebetween or degenerates thereof which do not alter the amino acid sequence encoded by said second cDNA; wherein (b) is located between (a) and (c); and the HGF construct simultaneously encodes two heterotypes of human HGF. 43. The hybrid HGF construct of claim 42, wherein said polynucleotide comprises 483-727 of SEQ ID NO: 2 and 4168-5423 of SEQ ID NO: 2 between exons 4 and 5. 44. The hybrid HGF construct of claim 43, wherein said polynucleotide comprises 483-727 of SEQ ID NO: 2 and 3168-5423 of SEQ ID NO: 2 between exons 4 and 5.

Details for Patent 7,812,146

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2022-03-20
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2022-03-20
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2022-03-20